to 2000) were searched and the reference lists of retrieved articles were checked. Conference abstracts and book chapters were also scanned. Trial authors and drug manufacturers were contacted.
Nine trials received the validity rating 'A' on the basis of adequate allocation concealment; allocation concealment was not described in the remaining trials and these were rated 'B'. Ninety per cent of the included trials were double-blind.
The main efficacy outcome reported was the presence of cocaine metabolites in the urine. The pooled results for each drug showed no significant differences between the active drug and placebo. Significant heterogeneity was present within 14 trials of desipramine (chi-squared 12.7, d.f.=6, P=0.048). Heterogeneity was still present when data for patients with opioid dependence were analysed separately. Data for the other efficacy outcomes were skewed or missing and could not be entered into the meta-analysis.
Ten trials did not report the drop-out rates. The drop-out rates in the remaining studies ranged from 0 to 84%. No statistically-significant differences were found between the active drugs and placebo, except in one small trial of fluoxetine, where significantly more people on fluoxetine completed the study (RR 0.53, 95% CI: 0.32, 0.88, n=32) .
No statistically-significant differences were found between the drug and placebo groups in terms of the risk of sideeffects.
Direct comparisons of drugs found no statistically-significant differences between amantadine and bromocriptine, or amantadine and desipramine. Similar results were obtained when trials where patients had a primary diagnosis of cocaine dependence were compared to trials of patients with cocaine and opioid dependence or patients on methadone maintenance treatment.
Authors' conclusions
The authors concluded that there is no current evidence to support the clinical use of carbamazepine, antidepressants, dopamine agonists, disulfiram, mazindol, phenytoin, nimodipine, lithium and NeuRecover-SA in the treatment of cocaine dependence. Larger RCTs should be conducted for the most promising medications. The high drop-out rate in the RCTs suggested that psychotherapeutic supportive measures may be useful in keeping patients in treatment programmes.
CRD commentary
This systematic review used a focused research question to generate appropriate study inclusion criteria. The literature search was comprehensive. It was not stated whether studies published in all languages were eligible for inclusion; if not, this may have led to some relevant studies being missed. Few details of the review process were given, but it was stated that the data were extracted independently, which reduces the potential for human error. The validity assessment focused on the adequacy of allocation concealment, which, since strongly related to the potential for bias in the results,
